Alkermes Appoints Joshua Reed as Chief Financial Officer
Rhea-AI Summary
Alkermes (Nasdaq: ALKS) has appointed Joshua Reed as Chief Financial Officer, effective September 15, 2025. Reed brings over 30 years of financial leadership experience in biotechnology and pharmaceutical sectors, most recently serving as CFO of Omega Therapeutics.
Reed's extensive background includes CFO roles at Aldeyra Therapeutics and leadership positions at Bristol Myers Squibb, where he served as Vice President and Head of Finance Operations for the U.S. and Puerto Rico. He currently serves on the board of Scholar Rock Holding Corporation and holds degrees from Rutgers University and the University of Michigan's Ross School of Business.
Positive
- Appointment of seasoned CFO with over 30 years of financial leadership experience
- Strong industry expertise from major companies including Bristol Myers Squibb
- Additional strategic insight from current board position at Scholar Rock
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ALKS declined 2.67%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
"I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.
Mr. Reed brings over 30 years of financial leadership experience, with a strong focus in the biotechnology and pharmaceutical sectors. Most recently, he served as CFO of Omega Therapeutics, a then publicly-traded biotechnology company. Prior to that, he was the CFO at Aldeyra Therapeutics. Earlier in his career, Mr. Reed spent more than a decade at Bristol Myers Squibb, culminating in his role as Vice President and Head of Finance Operations for the
Mr. Reed currently serves on the board of directors of Scholar Rock Holding Corporation, a publicly-traded biotechnology company. He earned a Bachelor of Science in Finance from Rutgers University and a Master of Business Administration from the University of
"We are pleased to welcome Joshua to Alkermes at such an exciting time in our company's evolution," said Mr. Pops. "Joshua brings a wealth of financial expertise and strategic insight from his extensive experience in the biopharmaceutical industry. We gain his financial acumen and dedication to excellence as we continue to focus on driving strong performance across our commercial business, advancing our pipeline, and delivering long-term shareholder value. I look forward to the positive impact he will have across our organization."
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contacts: | |||
For Investors: | Sandy Coombs | +1 781 609 6377 | |
For Media: | Katie Joyce | +1 781 249 8927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-appoints-joshua-reed-as-chief-financial-officer-302554407.html
SOURCE Alkermes plc
FAQ
Who is the new CFO of Alkermes (ALKS)?
What is Joshua Reed's previous experience before joining Alkermes?
What are Alkermes' (ALKS) main business areas?
When does Joshua Reed start as Alkermes CFO?
